

HPTN 052: Summary

Myron S. Cohen, MD
Protocol Chair

6th IAS Conference, Rome, Italy
July 18, 2011



HPTN 052: Session Highlights

- Early ART prevented linked transmission of HIV
- Unlinked transmissions were noted despite intensive couples counseling
- Early ART reduced the number of clinical events observed
- Regional differences in HIV transmission associated with ART were noted

ORIGINAL ARTICLE

Prevention of HIV-1 Infection with Early Antiretroviral Therapy

Myron S. Cohen, M.D., Ying Q. Chen, Ph.D., Marybeth McCauley, M.P.H.,
Theresa Gamble, Ph.D., Mina C. Hosseinipour, M.D.,
Nagalingeswaran Kumarasamy, M.B., B.S., James G. Hakim, M.D.,
Johnstone Kumwenda, F.R.C.P., Beatriz Grinsztejn, M.D., Jose H.S. Pilotto, M.D.,
Sheela V. Godbole, M.D., Sanjay Mehendale, M.D., Suwat Chariyalertsak, M.D.,
Breno R. Santos, M.D., Kenneth H. Mayer, M.D., Irving F. Hoffman, P.A.,
Susan H. Eshleman, M.D., Estelle Piwowar-Manning, M.T., Lei Wang, Ph.D.,
Joseph Makhema, F.R.C.P., Lisa A. Mills, M.D., Guy de Bruyn, M.B., B.Ch.,
Ian Sanne, M.B., B.Ch., Joseph Eron, M.D., Joel Gallant, M.D.,
Diane Havlir, M.D., Susan Swindells, M.B., B.S., Heather Ribaud, Ph.D.,
Vanessa Elharrar, M.D., David Burns, M.D., Taha E. Taha, M.B., B.S.,
Karin Nielsen-Saines, M.D., David Celentano, Sc.D., Max Essex, D.V.M.,
and Thomas R. Fleming, Ph.D., for the HPTN 052 Study Team*

HPTN 052: Implications

- The HIV prevention effect demonstrated in HPTN 052 is the proof of a concept
- These results could inform
 - The “Test and Treat” strategies
 - Management of HIV discordant couples

HPTN 052 Recognition

U.S. Sponsors:

- National Institute of Allergy and Infectious Diseases (NIAID) / U.S. National Institutes of Health (NIH)

HIV Prevention Trials Network (HPTN):

- Network Laboratory, Johns Hopkins University
- Statistical Center for HIV/AIDS Research & Prevention (SCHARP) and University of Washington
- Coordinating and Operations Center, Family Health International (FHI)
- HPTN Leadership

AIDS Clinical Trials Group (ACTG):

- ACTG Leadership and Investigators

Pharmaceutical Companies:

- Abbott Laboratories
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Bristol-Myers Squibb
- Gilead Sciences, Inc.
- GlaxoSmithKline/ViiV Healthcare
- Merck & Co., Inc.

Sites (Investigators of Record):

- Porto Alegre, Brazil (Breno Santos)
- Rio de Janeiro, Brazil (Beatriz Grinsztejn)
- Boston, United States (Kenneth Mayer)
- Chennai, India (N. Kumarasamy)
- Pune, India (Sheela Godbole)
- Chiang Mai, Thailand (Suwat Chariyalertsak)
- Gaborone, Botswana (Joseph Makhema)
- Kisumu, Kenya (Lisa Mills)
- Blantyre, Malawi (Johnstone Kumwenda)
- Lilongwe, Malawi (Mina Hosseinipour)
- Johannesburg, South Africa (Ian Sanne)
- Soweto, South Africa (Guy De Bruyn)
- Harare, Zimbabwe (James Hakim)

Study Participants!